8-K/A 1 smti_8k.htm FORM 8-K/A Blueprint
 

  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K/A
Amendment 1
 
Current Report
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 15, 2019
 
SANARA MEDTECH INC. 
(Exact name of registrant as specified in its charter)
 
 Texas
 000-11808
 59-2219994
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (I.R.S. Employer Identification No.)
 
 1200 Summit Avenue, Suite 414
Fort Worth, Texas
 
 76102
 (Address of principal executive offices)
 (zip code)

Registrant’s telephone number, including area code:(817)-529-2300
 
Securities registered pursuant to Section 12(b) of the Act: None
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
 
Explanatory Note
 
Sanara MedTech Inc. (the "Company”), formerly named Wound Management Technologies, Inc., previously filed a Current Report on Form 8-K, dated March 21, 2019, disclosing the acquisition of the remaining 50% equity interest in Cellerate, LLC not then owned by the Company. This amendment to the referenced Current Report is being filed solely to provide financial information required under Regulation S-X Rule 8-04 and 8-05 with respect to the Company’s acquisition of the remaining equity interests in Cellerate, LLC.
 
Item 9.01 Financial Statements and Exhibits.
 
a.
Audited balance sheet as of December 31, 2018
b.
Audited statement of operations for the period August 28, 2018 (inception) through December 31, 2018
c.
Audited statement of changes and members' capital through December 31, 2018  
d.
Audited statement of cash flows through December 31, 2018
 
a.
Pro forma combined balance sheet as of December 31, 2018
b.
Pro forma combined statement of operations for the twelve months ended December 31, 2018.
 
 
 
 
 
 
SIGNATURE
 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 Sanara MedTech Inc.
 
 
 
 
 
Date: August 13, 2019
By:  
/s/ Michael D. McNeil
 
 
 
 Name: Michael D. McNeil
 
 
 
 Title: Chief Financial Officer